Regeneron

We’re ready to make a difference! Next Friday kicks off our 8th annual Day for Doing Good (#RegeneronD4DG) — a week of global volunteerism that showcases the power of our team’s diverse talents, time and leadership to strengthen and support our local communities. Hear our colleagues around the world share their experiences with D4DG and get ready to be inspired by the over 350 projects we’re supporting this year. Stay tuned as we kick off an exciting week of giving back!

Join us in congratulating Aris Baras, SVP, Head of Regeneron Genetics Center and co-Head of Regeneron Genetic Medicines, on being named a PharmaVoice 100 honoree. His vision helps shape the future of genetics research at Regeneron and beyond, paving the way for innovative new treatments.? ? To hear more from him and other industry leaders, visit: https://bit.ly/4eTwAh0

Over the past few months, we had the pleasure of meeting racing fans at Darlington Raceway, Iowa Speedway, and Daytona International Speedway. We focused on the importance of skin protection and the risks of advanced non-melanoma skin cancer (NMSC), including advanced basal cell carcinoma (BCC) and advanced cutaneous squamous cell carcinoma (CSCC). It was great to connect with passionate fans and share resources to raise NMSC awareness and encourage regular skin checks with a dermatologist. Visit our website to learn more about advanced NMSC and our commitment to educating patients, caregivers, and the public about this important topic. https://bit.ly/4eLoCpZ

Every day we see advancements in digital health technologies, #AI, and #MachineLearning that positively enhance the drug development process. Integrating new tools, modalities, and more into our work creates efficiencies in how we collect, process, and analyze data to improve the #ClinicalTrials experience for patients and site teams. ? We spoke with STAT News about how we’re following the science to make it happen: https://bit.ly/3NeBKYR

Congratulations to our Board co-Chair, President and Chief Scientific Officer George Yancopoulos for accepting the STEM Education Award from the New York STEM Cell Foundation (NYSCF) on behalf of Regeneron. This award honors Regeneron's commitment to nurturing the next generation of innovators — a commitment we proudly share with NYSCF. By supporting young people in STEM, we empower them to push the boundaries of science, contribute to future medical breakthroughs and tackle society’s most pressing challenges. Learn more about our STEM programs: https://bit.ly/3N1Nmyp

Today at American Academy of Otolaryngology, we’re sharing new data on our investigational gene therapy for otoferlin-related hearing loss.?? ? These results are the latest in our efforts to advance gene therapy research as we investigate approaches that aim to address the root cause of genetic hearing loss. #OTOMTG24? ? Read more about our genetic medicines research: https://bit.ly/3Z3kNIk

At #ASBMR2024, we’re sharing new findings on the lived experiences with, and epidemiology of, fibrodysplasia ossificans progressiva (FOP). Check out our presentations to learn more: https://bit.ly/4gyVBzD

This week, our team is attending the American Academy of Otolaryngology (AAO-HNSF) 2024 Annual Meeting. We're dedicated to advancing auditory research through pioneering efforts in genetic medicines. Our aim is to make a meaningful impact on people living with hearing disorders.? ? Discover insights from Vassili Valayannopoulos, MD, PhD, MBA, Clinical Program Lead, Auditory Sciences, and Meghan Drummond, PhD, Director of Auditory Sciences, as they discuss our progress and the future of our auditory program for genetic forms of hearing loss: https://bit.ly/471kqQc.? ? #OTOMTG24

The pace of today’s clinical #innovation is a reason to celebrate, but it also requires our industry to look at how we evolve clinical trials. New tools, modalities, and technologies are driving the evolution of the #ClinicalTrials landscape, making trials more effective and agile. It’s also allowing us to improve a process that has stayed mostly the same for decades.? ? Join me at the #FierceClinicalSummit on Sept. 26 at 8:45 AM ET for a keynote addressing the current state of clinical research and approaches to modernizing clinical trials—including the promise of #GeneticMedicine—as we prepare for the future. ?? https://lnkd.in/eBJFnp95

We believe in the power of our scientific research to address unmet patient needs. Our latest research in heart failure — a leading cause of morbidity and mortality — published in Nature Portfolio’s print issue explores the potential of a novel investigational antibody to address heart failure. This therapeutic approach targets and activates a protein called natriuretic peptide receptor 1 (NPR1), resulting in the preferential lowering of venous?pressure, the primary driver of symptomatology in patients with heart failure.? ? Our preclinical and first-in-human clinical data from this study, in concert with a genetic analysis of over 700,000 individuals performed at our Regeneron Genetics Center (RGC), lays the groundwork for further studies to evaluate this treatment for patients with heart failure. Read more: https://lnkd.in/e7VsWCpi